Neumora Therapeutics, Inc. (NMRA)
2.55
-0.09
(-3.41%)
USD |
NASDAQ |
Mar 19, 12:11
Neumora Therapeutics Enterprise Value : 289.68M for March 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 856.41B |
| Protalix Biotherapeutics, Inc. | 155.08M |
| Nautilus Biotechnology, Inc. | 273.40M |
| Ventyx Biosciences, Inc. (DELISTED) | 816.41M |
| ProKidney Corp. | 1.353B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.76M |
| Total Expenses (Quarterly) | 56.76M |
| EPS Diluted (Quarterly) | -0.3507 |
| Earnings Yield | -57.38% |
| Normalized Earnings Yield | -56.54 |